AHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care
AHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care
The AMA MAP™ Hypertension Program in Action: Insights from Grace Health
The AMA MAP™ Hypertension Program in Action: Insights from Grace Health
Examining CVD in Lupus: Insights from a Diverse Population-Based Registry
Examining CVD in Lupus: Insights from a Diverse Population-Based Registry
Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
No benefit of routine spironolactone post-MI
No benefit of routine spironolactone post-MI
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
Heart Disease in Lupus: The Impact of Rural Residence on Hospitalizations
Heart Disease in Lupus: The Impact of Rural Residence on Hospitalizations
Coronary Risk in Rheumatoid Arthritis: Rural vs. Urban Hospitalization Disparities
Coronary Risk in Rheumatoid Arthritis: Rural vs. Urban Hospitalization Disparities
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
Tirzepatide reduces HF events in patients with HFpEF and obesity
Tirzepatide reduces HF events in patients with HFpEF and obesity
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
